{
    "clinical_study": {
        "@rank": "78767", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the use in clinical practice and efficacy of Mircera\n      (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients\n      not on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible\n      patients will be followed for 24 weeks."
        }, 
        "brief_title": "An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 to 65 years of age, inclusive\n\n          -  Patients with stage III-IV chronic kidney disease not on dialysis\n\n          -  ESA na\u00efve with Hb < 10 g/dL,  or on treatment with ESAs other than Mircera and Hb\n             within the target range of 10-12 g/dL\n\n          -  Adequate iron status as judged by the treating physician\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any\n             constituent of the study medication\n\n          -  Clinically significant concomitant disease or disorder as defined by protocol\n\n          -  Clinical suspicion of pure red cell aplasia (PRCA)\n\n          -  Planned elective surgery during the study period , except for cataract surgery or\n             vascular access surgery\n\n          -  Transfusion of red blood cells in the previous 2 months\n\n          -  Pregnant women\n\n          -  Contraindications for Mircera according to local prescribing information or as judged\n             by the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with stage III-IV chronic kidney disease not on dialysis receiving treatment with\n        Mircera for chronic renal anemia"
            }
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695746", 
            "org_study_id": "ML25476"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bhubaneswar", 
                        "country": "India", 
                        "zip": "751021"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "zip": "500 029"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "zip": "400012"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "zip": "400036"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vadodara", 
                        "country": "India", 
                        "zip": "390005"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vellore", 
                        "country": "India", 
                        "zip": "632006"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_groups": "1", 
        "official_title": "Efficacy of C.E.R.A. for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV , Not on Dialysis , Treated According to Routine Clinical Practice", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Drug Controller General"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Clinical/demographic patient characteristics at initiation of treatment with Mircera", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Mean time to achieve target Hb range (Hb 10-12 g/dL)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Maintenance of Hb levels (patients on ESA with HB 10-12 g/dL): Percentage of patients maintaining Hb level within 1 g/dL of baseline during study period (24 weeks)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695746"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients achieving Hb target range (Hb 10-12 g/dL) at least once during study treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Maintenance: Mean time spent on Hb level 10-12 g/dL)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Dosage/administration route", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}